Skip to main content
Premium Trial:

Request an Annual Quote

Tataa Biocenter, SimplicityBio Plan to Offer Biomarker Discovery Products

NEW YORK (GenomeWeb) – Sweden's Tataa Biocenter announced today that it has partnered with in silico solutions provider SimplicityBio to market products for biomarker discovery, signature optimization, and validation on a variety of platforms.

The partners will combine their products to offer a complete solution for biomarker discovery, assay and protocol optimization, analytical validation, standardization, and clinical validation, with the goal of developing diagnostics, prognostics, and theranostics based on reliable biomarker signatures. Platforms include microarrays, qPCR, dPCR, and next-generation sequencing, and almost any kind of biomarker with an emphasis on mRNA, microRNA, lncRNA, SNPs, CNVs, methylation markers, cfDNA, proteins, and circulating tumor cells.

Further terms of the deal were not disclosed.

Matthew Hall, CSO of Monthey, Switzerland-based SimplicityBio, said in a statement that Tataa's ability to generate genomic data based on its analysis pipelines is ideal for SimplicityBio's biomarker discovery and modeling pipelines.

The Scan

Comfort of Home

The Guardian reports that AstraZeneca is to run more clinical trials from people's homes with the aim of increasing participant diversity.

Keep Under Control

Genetic technologies are among the tools suggested to manage invasive species and feral animals in Australia, Newsweek says.

Just Make It

The New York Times writes that there is increased interest in applying gene synthesis to even more applications.

Nucleic Acids Research Papers on OncoDB, mBodyMap, Genomicus

In Nucleic Acids Research this week: database to analyze large cancer datasets, human body microbe database, and more.